Yamaguchi Tomoko, Matsuzaki Juntaro, Katsuda Takeshi, Saito Yoshimasa, Saito Hidetsugu, Ochiya Takahiro
1Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512 Japan.
2Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Inflamm Regen. 2019 Jul 2;39:13. doi: 10.1186/s41232-019-0102-4. eCollection 2019.
Liver and hepatocyte transplantation are the only effective therapies for late-stage liver diseases, in which the liver loses its regenerative capacity. However, there is a shortage of donors. As a potential alternative approach, functional hepatocytes were recently generated from various cell sources. Analysis of drug metabolism in the human liver is important for drug development. Consequently, cells that metabolize drugs similar to human primary hepatocytes are required. This review discusses the current challenges and future perspectives concerning hepatocytes and hepatic progenitor cells that have been reprogrammed from various cell types, focusing on their functions in transplantation models and their ability to metabolize drugs.
肝脏和肝细胞移植是晚期肝脏疾病的唯一有效治疗方法,在晚期肝脏疾病中肝脏失去了再生能力。然而,供体短缺。作为一种潜在的替代方法,最近已从各种细胞来源生成了功能性肝细胞。分析人类肝脏中的药物代谢对于药物开发很重要。因此,需要能够代谢与人类原代肝细胞相似药物的细胞。本综述讨论了从各种细胞类型重编程而来的肝细胞和肝祖细胞目前面临的挑战和未来前景,重点关注它们在移植模型中的功能以及代谢药物的能力。